In the context of tumor immunology, expression of ETAR has been reported in prostate cancer patients with bone metastasis [92] and HPV-induced neoplasia [93, 94], whereas ETBR expression was associated with the absence of tumor infiltrating lymphocytes and decreased survival time of ovarian cancer patients [91]. This evidence concerns the gene EDNRA and prostate carcinoma.